Linked Life Data

18479753

Source:http://linkedlifedata.com/resource/pubmed/id/18479753

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-6-24
pubmed:abstractText
Contraceptive vaccines based on hCGbeta have not met clinical application because of poor immunogenicity. In the present study, the eukaryotic expression vectors pCI-gs-signal-6His-hCGbeta and pCI-gs-signal-6His-hCGbeta-hC3d3 were constructed, and transfected into CHO cells with aid of Lipofectaine 2000 reagent to gain the secretory recombinant protein. Isolated B cells from human peripheral blood, combined B cells with T cells, and PBMC were treated in vitro, respectively, with 1 nM, 10 nM, 100 nM hCGbeta, hCGbeta-hC3d3 or PWM for 12 days. Immunoglobulin (Ig) and anti-hCG antibody levels in the supernatant were measured by an indirect enzyme-linked immunosorbent assay (ELISA). The expressions of CD80/CD86 on B cells, and CD154/CD25 on T cells, were analyzed by flow cytometry (FCM), and IL-2 production was assayed by ELISA. It was found that the Ig levels in the B-cell supernatants, the combined B with T cells, and PBMC treated with 100 nM hCGbeta-C3d3 fusion protein were 4-fold, 10-fold and 10.9-fold more, respectively, than that of hCGbeta. The anti-hCG antibody could be produced in the combined B cells with T cells, as well as PBMC challenged with 100 nM hCGbeta-C3d3, but no anti-hCG antibody was produced in the challenge with hCGbeta. The hCGbeta-hC3d3 fusion protein enhanced the expression of CD80 and CD86 on B cells, especially CD86 (P<0.05), and significantly increased the expression of CD154 and CD25 molecules on T cells compared to that of hCGbeta (P<0.05). The hCGbeta-hC3d3 promoted human PBMC producing more IL-2 than hCGbeta. These findings indicate that the fusion of hC3d3 to hCGbeta, as a means of harnessing the adjuvant potential of the innate immune system, may contribute to a more efficient humoral immune response, and might provide a potential application of protein vaccine strategies in humans in the future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0165-0378
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
115-24
pubmed:meshHeading
pubmed-meshheading:18479753-Animals, pubmed-meshheading:18479753-Antigens, CD80, pubmed-meshheading:18479753-Antigens, CD86, pubmed-meshheading:18479753-B-Lymphocytes, pubmed-meshheading:18479753-CD40 Ligand, pubmed-meshheading:18479753-CHO Cells, pubmed-meshheading:18479753-Chorionic Gonadotropin, beta Subunit, Human, pubmed-meshheading:18479753-Complement C3d, pubmed-meshheading:18479753-Cricetinae, pubmed-meshheading:18479753-Cricetulus, pubmed-meshheading:18479753-Humans, pubmed-meshheading:18479753-Interleukin-2, pubmed-meshheading:18479753-Interleukin-2 Receptor alpha Subunit, pubmed-meshheading:18479753-Lymphocyte Cooperation, pubmed-meshheading:18479753-Recombinant Fusion Proteins, pubmed-meshheading:18479753-T-Lymphocytes, pubmed-meshheading:18479753-Transfection, pubmed-meshheading:18479753-Vaccines, Contraceptive
pubmed:year
2008
pubmed:articleTitle
Fusion of hC3d3 to hCGbeta enhances responsiveness in vitro of human peripheral immunocompetent cells upon the antigen primary challenge.
pubmed:affiliation
Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics & Gynecology, Fudan University Shanghai Medical College, Shanghai, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't